Cover Image
市場調查報告書

癌症治療查核點抑制劑的全球市場的預測 (2017∼2027年):PD-1抑制劑、CTLA-4抑制劑、開發中產品的未來展望分析

Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs

出版商 Visiongain Ltd 商品編碼 346762
出版日期 內容資訊 英文 139 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症治療查核點抑制劑的全球市場的預測 (2017∼2027年):PD-1抑制劑、CTLA-4抑制劑、開發中產品的未來展望分析 Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs
出版日期: 2017年10月25日 內容資訊: 英文 139 Pages
簡介

全球癌症治療查核點抑制劑的市場規模,2017年達到了76億美元以上。在不遠的將來 (2027年) 也預計持續大幅度的正成長。

本報告提供癌症治療用的查核點抑制劑的市場相關調查,產品、治療方法概要,及市場基本結構,市場發展前景 (今後11年),各產品、各地區的詳細趨勢,主要開發平台趨勢,推動及阻礙市場要素,主要企業的簡介的資訊彙整,為您概述為以下內容。

第1章 報告概要

第2章 癌症治療查核點抑制劑市場:簡介

  • 查核點抑制劑:免疫療法的新時代
  • 腫瘤治療中查核點抑制劑的利用

第3章 癌症治療查核點抑制劑:全球市場的主要企業

  • 主要企業的最新趨勢
    • Yervoy (Ipilimumab):Bristol-Myers Squibb
    • Opdivo (Nivolumab):Bristol-Myers Squibb/小野藥品工業
    • Keytruda (Pembrolizumab):Merck & Co.
  • 主要企業間的競爭狀態
    • Bristol-Myers Squibb主導市場

第4章 癌症治療查核點抑制劑市場:未來展望

  • 全球癌症治療查核點抑制劑市場:最新形勢
  • 世界市場趨勢預測 (今後11年份)
  • 個別市場趨勢預測 (今後11年份)
    • CTLA-4抑制劑市場
    • PD-1抑制劑市場
    • 市場佔有率的變化:PD-1抑制劑領導市場
    • 推動及阻礙市場要素

第5章 癌症治療查核點抑制劑市場:主要國家的情況

  • 各地區的市場佔有率 (最新值)
  • 各地區的市場趨勢預測 (今後11年份)
    • 各地區市場佔有率的變動預測
  • 美國市場 (今後11年份)
  • 歐洲市場 (今後11年份)
    • 德國,法國,義大利,英國,西班牙
  • 日本市場 (今後11年份)
  • 亞太地區市場 (今後11年份)

第6章 癌症治療查核點抑制劑市場:開發平台分析

  • 抗PD-1抑制劑和抗PD-L1抑制劑
    • Tecentriq (Atezolizumab)
    • Imfinizi (durubarumabu)
    • Bavencio-Avelumab (MSB0010718C):Merck KGaA/Pfizer
    • Pidilizumab (CT-011):CureTech Ltd
    • AMP-224:GSK/Amplimmune
    • TSR-042:TESARO Bio/AnaptysBio
    • AMP-514 (MEDI0680):AstraZeneca/MedImmune
    • REGN2810:Regeneron/Sanofi
  • CTLA-4抑制劑
    • Tremelimumab (CP-675,206):AstraZeneca
  • LAG-3 (淋巴球活性化遺傳基因3) 抑制劑
    • IMP321:Prima Biomed
    • BMS-986016:Bristol-Myers Squibb
    • IMP701:Prima BioMed/Novartis
  • KIR抑制劑
    • ririrumabu (IPH2102/BMS-986015):Innate Pharma/Bristol-Myers Squibb
  • 抗NKG2A抑制劑
    • IPH2201:Innate Pharma/AstraZeneca/MedImmune
  • 其他查核點抑制劑
    • VISTA抑制劑
    • CA-170:Curis Inc/Aurigene Discovery Technologies
  • IDO、TDO抑制劑
    • Indoximod (NLG-9189):NewLink Genetics
    • NLG919:NewLink Genetics
    • INCB024360:Incyte/Roche
  • A2aR抑制劑
    • HTL-1071:AstraZeneca/Heptares
    • 未來的開發平台研究的範圍

第7章 癌症治療查核點抑制劑市場:定性分析

  • SWOT分析 (今後11年份)
  • 癌症治療查核點抑制劑市場優勢、弱點
    • 使用免疫系統巨大的潛力,創新的治療方法
    • 治療費高吸引企業
    • 治療成本高,今後也將成為市場進入的障礙
    • 副作用阻礙市場成長
  • 癌症治療查核點抑制劑市場機會、威脅
    • 使用了生物標記,最適合的利用法的確立
    • 聯合治療改善治療效果
    • 由於藥物治療的成本高,對醫療制度的不良影響
    • 相似的產品氾濫的市場

第8章 結論

  • 全球癌症治療查核點抑制劑市場未來展望
    • 成長促進因素:強力嶄新的開發平台醫藥品的存在
  • 維持主要國家市場未來展望:美國、歐洲主導權
  • 癌症治療查核點抑制劑市場的未來
  • Visiongain的相關分析

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0252

Where is the Checkpoint Inhibitors for Treating Cancer market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 139-page report provides 96 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Checkpoint Inhibitors for Treating Cancer market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, there are forecasts for 3 submarkets and 7 Drugs in the report at a global level, as well as profiles for 19 pipeline drug candidates

Global Checkpoint Inhibitors for Treating Cancer Market by Type

  • PD-1 Inhibitors
  • CLTA-4 Inhibitors
  • Pipeline Drugs

Global Checkpoint Inhibitors for Treating Cancer Market by Drug

  • Opdivo (nivolumab)
  • Keytruda (pembrolizumab)
  • Yervoy (ipilimumab)
  • Tecentriq (Atezolizumab)
  • Imfinizi (Durvalumab)
  • Bavencio - Avelumab - (MSB0010718C)
  • Tremelimumab (CP-675,206)

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 8 major regional/national markets:

  • The US
  • Japan
  • Germany
  • The UK
  • Italy
  • France
  • Spain
  • Asia-Pacific

The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer market, with a focus on this segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, the US, the UK and the APAC region in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth

Overall world revenue for Checkpoint Inhibitors for Treating Cancer will surpass $7.6bn in 2017, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Checkpoint Inhibitors for Treating Cancer Market report helps you

In summary, our 139-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the Checkpoint Inhibitors for Treating Cancer market, with forecasts for 3 submarkets and 7 Drugs, each forecasted at a global level - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 8 key regional and national markets - See forecasts for the Checkpoint Inhibitors for Treating Cancer in Asia-Pacific, the US, Germany, France, the UK, Italy, France, and Japan,
  • What stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market - including company profiles for some of the major companies involved in the Checkpoint Inhibitors for Treating Cancer market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain's study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer market and leading companies. You will find data, trends and predictions.

Get our report today Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016
  • 1.2. Benefits of This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methods of the Study
  • 1.7. Frequently Asked Questions(FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2016

  • 2.1. Checkpoint Inhibitors: A New Era in Immunotherapy
  • 2.2. Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2017-2027 and Leading Companies in the World Market

  • 3.1. Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2016
    • 3.1.1. Yervoy(ipilimumab)-Bristol-Myers Squibb
      • 3.1.1.1. Yervoy: Sales Analysis
    • 3.1.2. Opdivo(nivolumab)-Bristol-Myers Squibb/Ono Pharmaceutical
      • 3.1.2.1. Opdivo: Sales Analysis
    • 3.1.3. Keytruda(pembrolizumab)-Merck & Co.
      • 3.1.3.1. Keytruda: Sales Analysis
  • 3.2. Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2016
    • 3.2.1. Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2017-2027

  • 4.1. The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2016
  • 4.2. The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2017-2027
  • 4.3. Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2017-2027
    • 4.3.1. The CTLA-4 Inhibitors Submarket Forecast 2017-2027
    • 4.3.2. The PD-1 Inhibitors Submarket Forecast 2017-2027
    • 4.3.3. Changing Market Shares: PD-1 Inhibitors Will Lead the Market
    • 4.3.4. Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
      • 4.3.4.1. Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
      • 4.3.4.2. Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027

  • 5.1. Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2017-2027
  • 5.2. World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2017-2027
    • 5.2.1. How Will Regional Market Shares Change to 2027?
  • 5.3. The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
  • 5.4. The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
    • 5.4.1. Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
    • 5.4.2. France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
    • 5.4.3. Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
    • 5.4.4. The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
    • 5.4.5. Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
  • 5.5. Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
  • 5.6. The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2017-2027

  • 6.1. Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
    • 6.1.1. Tecentriq(Atezolizumab)
    • 6.1.2. Imfinizi(Durvalumab)
    • 6.1.3. Bavencio-Avelumab-(MSB0010718C)-Merck KGaA/Pfizer
    • 6.1.4. Pidilizumab(CT-011)-CureTech Ltd
    • 6.1.5. AMP-224-GSK/Amplimmune
    • 6.1.6. TSR-042-TESARO Bio/AnaptysBio
    • 6.1.7. AMP-514(MEDI0680)-AstraZeneca/MedImmune
    • 6.1.8. REGN2810-Regeneron/Sanofi
  • 6.2. CTLA-4 Inhibitors
    • 6.2.1. Tremelimumab(CP-675,206)-AstraZeneca
  • 6.3. LAG-3(lymphocyte activation gene-3) Inhibitors
    • 6.3.1. IMP321- Prima Biomed
    • 6.3.2. BMS-986016-Bristol-Myers Squibb
    • 6.3.3. IMP701-Prima BioMed/Novartis
  • 6.4. KIR Inhibitors
    • 6.4.1. Lirilumab(IPH2102/BMS-986015)-Innate Pharma/Bristol-Myers Squibb
  • 6.5. Anti-NKG2A Inhibitors
    • 6.5.1. IPH2201-Innate Pharma/AstraZeneca/MedImmune
  • 6.6. Other Checkpoint Inhibitors
    • 6.6.1. VISTA Inhibitors
  • 6.6.1.1. CA-170-Curis Inc/Aurigene Discovery Technologies
    • 6.6.2. IDO and TDO Inhibitors
      • 6.6.2.1. Indoximod(NLG-9189)-NewLink Genetics
      • 6.6.2.2. NLG919-NewLink Genetics
      • 6.6.2.3. INCB024360-Incyte/Roche
    • 6.6.3. A2aR Inhibitors
      • 6.6.3.1. HTL-1071-AstraZeneca/Heptares
    • 6.6.4. Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027

  • 7.1. SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
  • 7.2. Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
    • 7.2.1. A Novel Treatment Method that Harnesses the Immune System's Vast Potential
    • 7.2.2. Pricing of the Treatments Will Attract Companies
    • 7.2.3. Cost of Treatment Will Restrain Market Access
    • 7.2.4. Side Effects May Prohibit Growth
  • 7.3. Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
    • 7.3.1. Biomarkers Pave the Way for Optimum Utility
    • 7.3.2. Combination Therapies Are Achieving Superior Results
    • 7.3.3. The Cost Burden of Expensive Drug Treatments on Healthcare Systems
    • 7.3.4. Crowding of the Market with Similar Products

8. Conclusions

  • 8.1. The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
    • 8.1.1. Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2027
  • 8.2. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027: The US and EU Will Retain Their Lead
  • 8.3. The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2016
  • Figure 3.1: Yervoy(ipilimumab): Historical Sales($bn), 2013-2016
  • Figure 3.2: Yervoy Forecast, Revenue($bn), 2016-2027
  • Figure 3.3: Opdivo Forecast, Revenue($bn), 2016-2027
  • Figure 3.4: Keytruda Forecast, Revenue($bn),2016-2027
  • Figure 3.5: Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2016
  • Figure 3.6: Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2017
  • Figure 4.1: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class(%), 2016
  • Figure 4.2: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes($bn), 2016-2027
  • Figure 4.3: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class(%), 2016
  • Figure 4.4: Global Market Forecast for CTLA-4 Inhibitors: Revenue($bn), 2016-2027
  • Figure 4.5: Global Market Forecast for PD-1 Inhibitors: Revenue($bn), 2016-2027
  • Figure 4.6: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class(%), 2022
  • Figure 4.7: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class(%), 2027
  • Figure 5.1: Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares(%), 2016
  • Figure 5.2: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes($bn), 2016-2027
  • Figure 5.3: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares(%), 2022
  • Figure 5.4: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares(%), 2027
  • Figure 5.5: Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 5.6: Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 5.7: EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country(%), 2016
  • Figure 5.8: Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes($bn), 2016-2027
  • Figure 5.9: Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 5.10: Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2017-2027
  • Figure 5.11: Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 5.12: Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 5.13: Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 5.14: Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 5.15: Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), 2016-2027
  • Figure 6.1: Tecentriq Forecast: Revenue($bn), 2016-2027
  • Figure 6.2: Imfinizi Forecast: Revenue($bn), 2016-2027
  • Figure 6.3: Bavencio Forecast: Revenue($bn), 2016-2027
  • Figure 6.4: Tremelimumab Forecast: Revenue($bn), 2016-2027
  • Figure 8.1: Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes($bn), 2016-2027
  • Figure 8.2: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size($bn), 2016, 2018, 2022, and 2027

List of Tables

  • Table 2.1: Main Types of Checkpoint Inhibitors in Development, 2016
  • Table 3.1: Yervoy(Ipilimumab): Historical Sales($bn, AGR%), 2013-2016
  • Table 3.2: Yervoy Forecast, Revenue($bn), Annual Growth(%), CAGR(%), 2016-2022
  • Table 3.3: Yervoy Forecast, Revenue($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 3.4: Opdivo Forecast, Revenue($bn), Annual Growth(%), CAGR(%), 2016-2022
  • Table 3.5: Opdivo Forecast, Revenue($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 3.6: Keytruda Forecast, Revenue($bn), Annual Growth(%), CAGR(%), 2016-2022
  • Table 3.7: Keytruda Forecast, Revenue($bn), Annual Growth(%), CAGR(%),2022-2027
  • Table 3.8: Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue($bn), Market Share(%), 2016
  • Table 3.9: Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue($bn), Market Share(%), 2017
  • Table 4.1: Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues($bn) and Market Shares(%) by Class, 2016
  • Table 4.2: Checkpoint Inhibitors by Revenue($bn), 2016
  • Table 4.3: Checkpoint Inhibitors by Revenue($bn), 2017
  • Table 4.4: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes($bn), Annual Growth Rates(%), CAGR(%), 2016-2022
  • Table 4.5: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes($bn), Annual Growth Rates(%), CAGR(%), 2022-2027
  • Table 4.6: Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues($bn) and Market Shares(%) by Class, 2016
  • Table 4.7: Global Market Forecast for CTLA-4 Inhibitors: Revenue($bn), Annual Growth Rate(%), CAGR(%), 2016-2022
  • Table 4.8: Global Market Forecast for CTLA-4 Inhibitors: Revenue($bn), Annual Growth Rate(%), CAGR(%), 2022-2027
  • Table 4.9: Global Market Forecast for PD-1 Inhibitors: Revenue($bn), Annual Growth Rate(%), CAGR(%), 2016-2022
  • Table 4.10: Global Market Forecast for PD-1 Inhibitors: Revenue($bn), Annual Growth Rate(%), CAGR(%), 2022-2027
  • Table 4.11: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares(%), 2016-2022
  • Table 4.12: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares(%), 2022-2027
  • Table 4.13: Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market,2017-2027
  • Table 5.1: Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes($bn), Market Shares(%), 2016
  • Table 5.2: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes($bn), Annual Growth(%), CAGRs(%),2016-2022
  • Table 5.3: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes($bn), Annual Growth(%), CAGRs(%), 2022-2027
  • Table 5.4: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares(%), 2016-2022
  • Table 5.5: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares(%), 2022-2027
  • Table 5.6: Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2016-2022
  • Table 5.7: Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.8: EU Market Shares(%), 2016-2022
  • Table 5.9: EU Market Shares(%), 2022-2027
  • Table 5.10: Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2017-2022
  • Table 5.11: Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.12: Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2016-2022
  • Table 5.13: Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.14: Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2017-2022
  • Table 5.15: Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.16: Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2017-2022
  • Table 5.17: Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.18: Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2016-2022
  • Table 5.19: Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.20: Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2016-2022
  • Table 5.21: Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.22: Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2017-2022
  • Table 5.23: Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 5.24: Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2017-2022
  • Table 5.25: Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size($bn), Annual Growth(%), CAGR(%), 2022-2027
  • Table 6.1: Selected Combination Therapies for Atezolizumab, 2016
  • Table 6.2: Tecentriq Forecast: Revenue($bn), 2017-2022
  • Table 6.3: TecentriqForecast: Revenue($bn), 2022-2027
  • Table 6.4: Imfinizi Forecast: Revenue($bn), 2017-2022
  • Table 6.5: Imfinizi Forecast: Revenue($bn), 2022-2027
  • Table 6.6: Bavencio Forecast: Revenue($bn), 2016-2022
  • Table 6.7: Bavencio Forecast: Revenue($bn), 2022-2027
  • Table 6.8: Tremelimumab Forecast: Revenue($bn), 2016-2027
  • Table 6.9: Tremelimumab Forecast: Revenue($bn), 2022-2027
  • Table 7.1: Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2016
  • Table 7.2: Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015
  • Table 8.1: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size($bn), Market Share(%), CAGR(%), 2016, 2018, 2022, and 2027
  • Table 8.2: Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size($bn), Market Share(%), CAGR(%), 2016, 2018, 2022, and 2027

Companies Listed

  • AbbVie
  • Agilent Technologies
  • Amgen
  • Amplimmune
  • AnaptysBio
  • AstraZeneca
  • Aurigene Discovery Technologies
  • Bristol-Myers Squibb
  • Celgene
  • CoStim Pharmaceuticals
  • CureTech Ltd
  • Curis Inc
  • Daiichi Sankyo
  • Dako(subsidiary of Agilent Technologies)
  • DMC(Data Monitoring Committee)
  • DNAtrix
  • Dynavax
  • Eddingpharm
  • GlaxoSmithKline(GSK)
  • Heptares
  • Immutep
  • Incyte
  • Innate Pharma
  • INSERM
  • iTeos Therapeutics
  • J&J
  • Medarex
  • MedImmune
  • Medivation Inc
  • Merck & Co.
  • Merck KGaA
  • Mirati Therapeutics
  • NEC Corporation
  • NewLink Genetics
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceutical
  • Pfizer
  • Pharmacyclics
  • Plexxikon(subsidiary of Daiichi Sankyo)
  • Prima Biomed
  • Regeneron
  • Roche
  • Sanofi
  • Sosei Group Corporation
  • Syndax
  • TESARO Inc
  • Teva Pharmaceutical Industries

List of Organizations:

  • American Cancer Society
  • ASCO(American Society of Clinical Oncology)
  • CHMP(Committee for Medicinal Products for Human Use)
  • Commission de la Transparence
  • CRI(Cancer Research Institute)
  • EMA(European Medicines Agency)
  • European Organisation for Research and Treatment and Cancer(EORTC)
  • FDA(US Food and Drug Administration)
  • French National Authority for Health
  • IGR(Institut Gustav Roussy)
  • LICR(Ludwig Cancer Research)
  • MHLW(Ministry of Health, Labour, and Welfare)
  • MHRA(Medicines and Healthcare Products Regulatory Agency)
  • NHS(National Health Service)
  • NICE(the National Institute for Health and Care Excellence)
  • Paris University
  • QIMR Berghofer Medical Research Institute
  • The de Duve Institute
  • WHO(World Health Organization)
  • Yamaguchi University
Back to Top